TScan Therapeutics (TCRX) reported third-quarter 2026 revenue of $0.6 million and a net loss of $33.1 million, compared with revenue of $2.5 million and a net loss of $35.7 million in the prior-year quarter.
The company announced a strategic reorganization focused on in vivo-engineered TCR-T therapies for solid tumors. Its PRAME- and MAGE-A4-targeted candidates are in IND-enabling studies, with a first patient dose targeted for the fourth quarter of 2027.
- Net loss per basic and diluted share was $0.25, compared with $0.28 a year earlier.
- Research and development expense was $25.3 million, down from $31.7 million.
- General and administrative expense was $8.3 million, up from $7.9 million.
- Cash and cash equivalents totaled $73.0 million at September 30, 2026, excluding $5.0 million of restricted cash.
- TScan said its cash resources are expected to fund operations into the fourth quarter of 2027.
- The company paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 and is seeking strategic partners for its heme malignancies and autoimmunity programs.
$TCRX Hedge Fund Activity
We have seen 25 institutional investors add shares of $TCRX stock to their portfolio, and 23 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ABERDEEN GROUP PLC removed 918,020 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $899,751
- BLACKROCK, INC. removed 846,298 shares (-46.0%) from their portfolio in Q2 2026, for an estimated $829,456
- BOOTHBAY FUND MANAGEMENT, LLC added 772,241 shares (+inf%) to their portfolio in Q2 2026, for an estimated $756,873
- TWO SIGMA INVESTMENTS, LP added 740,595 shares (+61.3%) to their portfolio in Q2 2026, for an estimated $725,857
- D. E. SHAW & CO., INC. added 478,975 shares (+689.9%) to their portfolio in Q2 2026, for an estimated $469,443
- MARSHALL WACE, LLP added 450,018 shares (+189.6%) to their portfolio in Q2 2026, for an estimated $441,062
- ACADIAN ASSET MANAGEMENT LLC added 386,627 shares (+29.6%) to their portfolio in Q3 2026, for an estimated $121,594
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
